Weaver Capital Management LLC Has $1.37 Million Holdings in Stryker Corporation (NYSE:SYK)

Weaver Capital Management LLC boosted its holdings in shares of Stryker Corporation (NYSE:SYK) by 1.2% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,674 shares of the medical technology company’s stock after acquiring an additional 44 shares during the quarter. Weaver Capital Management LLC’s holdings in Stryker were worth $1,368,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Stryker by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 32,698,828 shares of the medical technology company’s stock worth $11,773,213,000 after purchasing an additional 252,188 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Stryker by 0.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 11,109,722 shares of the medical technology company’s stock worth $4,000,056,000 after purchasing an additional 54,693 shares in the last quarter. FMR LLC raised its stake in shares of Stryker by 10.0% during the 4th quarter. FMR LLC now owns 8,034,844 shares of the medical technology company’s stock worth $2,892,946,000 after purchasing an additional 727,850 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Stryker by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 7,073,562 shares of the medical technology company’s stock worth $2,539,033,000 after purchasing an additional 168,436 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Stryker during the 4th quarter worth about $1,710,744,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Price Performance

Shares of NYSE:SYK opened at $375.44 on Friday. Stryker Corporation has a 1-year low of $314.93 and a 1-year high of $406.19. The firm has a market capitalization of $143.30 billion, a PE ratio of 50.73, a PEG ratio of 2.81 and a beta of 0.91. The business’s 50 day moving average is $374.95 and its 200-day moving average is $375.30. The company has a current ratio of 1.64, a quick ratio of 1.00 and a debt-to-equity ratio of 0.69.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, beating the consensus estimate of $2.73 by $0.11. The business had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. Stryker had a return on equity of 23.74% and a net margin of 12.31%. Stryker’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.50 EPS. Sell-side analysts predict that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be issued a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.89%. The ex-dividend date is Monday, June 30th. Stryker’s payout ratio is presently 45.41%.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the transaction, the director now owns 3,417,326 shares of the company’s stock, valued at $1,288,195,208.96. This represents a 5.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 5.90% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a research note on Monday, May 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $442.00 price target on shares of Stryker in a research note on Friday, March 21st. The Goldman Sachs Group set a $422.00 price target on Stryker in a research note on Tuesday, March 4th. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a report on Saturday, June 14th. Finally, Roth Mkm boosted their target price on Stryker from $405.00 to $456.00 and gave the stock a “buy” rating in a report on Friday, May 2nd. Four analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $427.30.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.